Education, Science, Technology, Innovation and Life
Open Access
Sign In

Overview of Traditional Chinese and Western Medicine Treatment of IgA Nephropathy

Download as PDF

DOI: 10.23977/medsc.2021.020205 | Downloads: 8 | Views: 838


Huiguang Li 1, Jian Shi 2


1 First School of clinical medicine, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China
2 Shaanxi Province Traditional Chinese Medical hospital, Xi’an 710000, Shaanxi, China

Corresponding Author

Jian Shi


IgA nephropathy is a kidney disease in which the deposition of IgA-based immune complexes in the mesangial region of the glomerulus is the main pathological feature. It is the most common primary glomerular disease in the world, and it is the main cause of ESRD patients in my country. Because its etiology and pathogenesis are not yet clear, there is currently no unified treatment plan. The drugs commonly used in western medicine to treat IgA nephropathy include angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, glucocorticoids and other immunosuppressive agents. Traditional Chinese medicine has unique advantages in the treatment of IgA nephropathy. It carries out individualized syndrome differentiation and treatment based on the stage and type of the disease, combined with the personal experience of doctors, and has significant clinical effects. Therefore, we should give full play to the advantages of the integration of Chinese and Western medicine, and intensify the exploration of Chinese and Western medicine treatment options. This article reviews the research progress of IgA nephropathy in traditional Chinese medicine and western medicine.


IgA nephropathy, Traditional Chinese medicine treatment, Western medicine treatment; Research progress, Clinical Experience


Huiguang Li, Jian Shi. Overview of Traditional Chinese and Western Medicine Treatment of IgA Nephropathy. MEDS Clinical Medicine (2021) 2: 17-24. DOI:


[1] Mestecky J, Novak J, Moldoveanu Z, et al.IgA nephropathy enigma[J]. Clin Immunol, 2016, 172: 72-77.
[2] Shang S, Li XK.The Role of Immune Modulation in Pathogenesis of IgA Nephropathy.Front Med, 2020, 7(92): 63-67.
[3] Li Lei-Shi, Liu Zhi-Hong. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. [J]. Kidney international, 2004, 66(3).
[4] Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, et al.TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int. (2020) 97:340–9. doi: 10.1016/j.kint.2019. 08.022
[5] Maillard N, Wyatt RJ, Julian BA, et al. Current understandingof the role of complement in IgA nephropathy. J Am SocNephrol, 2015, 26(7): 1503-1512.
[6] Roos A, Bouwman LH, Van Gijlswijk Janssen DJ, et al.Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol, 2001, 167(5): 2861-2868.
[7] Pei Y, Xu Y, Ruan J, et al. Plasma oxidative stress level of IgA nephropathy in children and the effect of early intervention with angiotensin-converting enzyme inhibitors [J]. J Renin Angiotensin Aldosterone Syst, 2016, 17(2): 1470320316647240.
[8] Szeto CC, Kwan BC, Chow KM, et al. The safety and shortterm efficacy of aliskiren in the treatment of immunoglobulin a nephropathy -a randomized cross-over study [J].PLoS One, 2013, 8(5): e62736.
[9] Huang JL, Yu SW, Yu DR, et al. The progress of glucocorticoid in the treatment of IgA nephropathy [J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2018, 19(5): 430-432.
[10] Lie CH, Xie YS, Chen XM. Evidence-based study of glucocorticoid in the treatment of IgA nephropathy [J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2008, 9(3): 273-275.
[11] Lv J, Xu D, Perkovic V, et al. Corticosteroid therapy in IgA nephropathy [J]. J Am Soc Nephrol, 2012, 23(6): 1108-1116.
[12] Rauen T, Eitner F, Fitzner C, et al. Intensive SupportiveCare plus Immunosuppression in IgA Nephropathy[J].NEngl J Med, 2015, 373(23): 2225-2236.
[13] Fellström BC, Barratt J, Cook H, et al.Targeted-release budesonide versus placebo in patients with IgA nephropathy(NEFIGAN): a double -blind, randomised, placebo-controlled phase 2b trial [J]. Lancet, 2017, 389(10084): 2117-2127.
[15] Peters HP, van den Brand JA, Berger SP, et al.Immunosuppressive therapy in patients with IgA nephropathy[J].Neth J Med,2015,73(6):284-289.
[16] Hogg RJ,  Bay RC,  Jennette JC,et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy[J].Am J Kidney Dis, 2015, 66(5): 783-791.
[17] Zheng JN, Bi TD, Zhu LB, et al. Efficacy and safety of mycophenolate mofetil for IgA nephropathy: An updated meta-analysis of randomized controlled trials [J]. Exp Ther Med, 2018, 16(3): 1882-1890.
[18] Liu YF, Wang Y. Director Fu Yi's Experience in Treating IgA Nephropathy [J]. Medical Information, 2020, 33(21): 155-156.
[19] Fan YJ, He RM, Yang SD, et al. Professor Li Shunmin's experience in treating IgA nephropathy [J]. Journal of Chengdu University of Traditional Chinese Medicine, 2018, 41(3): 91-94.
[20] Tao R, Deng YY,Chen WJ, et al. Analysis of TCM Syndromes of 209 Cases of IgA Nephropathy and Correlation Study with Clinical Indicators [J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2011, 12(11): 982-987.
[21] Wang XQ, Huang JJ,Xie YX,et al. Professor Wei Shi's experience in treating IgA nephropathy [J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2017, 18(6): 529-530.
[22] Ding N, Liu M. Professor Liu Ming's experience in treating hematuria in IgA nephropathy [J]. Guide of China Medicine, 2018, 16(1): 185-186.
[23] Li GH,Guan J,Zhang L,Zhang D. Professor Zhang Duo's experience in diagnosis and treatment of IgA nephropathy [J]. Nei Mongol Journal of Traditional Chinese Medicine, 2020, 39(12): 66-67.
[24] Wang JD,Zhao CBW,Yu WC,et al. Professor Qiu Moyan's experience in the treatment of IgA nephropathy from "Tiao Bu Fen Hua" [J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2017, 18(6): 475-477.
[25] Wang GQ, Mi XH. Mi Xiuhua's Experience in Treating IgA Nephropathy [J]. JOURNAL OF CHINESE RESEARCH HOSPITALS, 2017, 4(5): 40-43.
[26] Yang Y. Professor Ye Chuanhui's clinical experience in treating IgA nephropathy [J]. Journal of Sichuan Traditional Chinese Medicine, 2018, 36(10): 12-13.

Downloads: 3894
Visits: 168926

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.